EMBER-3: A Randomized, Open-Label, Phase 3 Study of LY3484356 vs Investigator's Choice of Endocrine Therapy, in Patients with Estrogen Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated with Endocrine Therapy
Study of Drug - LY3484356 in Patients with Breast Cancer (ER+, HER2-)
Sponsor: Eli lilly
Enrolling: Male and Female Patients
IRB Number: AAAT8041
U.S. Govt. ID: NCT03081234
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: This study is being done to see how safe an investigational drug, LY3484356 is and how well it will work to help people with estrogen receptor-positive (ER+), HER2 negative (HER2-) locally advanced or metastatic breast cancer previously treated with endocrine therapy. The main reason for you to take part in this study is not to treat you for your condition but to help in answering the following research question: How LY3484356 compares to the investigator's choice of either fulvestrant or exemestane for the treatment of ER+, HER2- breast cancer?
Meghna Trivedi, MD
Do You Qualify?
Are you able to swallow capsules/tablets? Yes No
Do you have a serious heart condition? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Research Nurse Navigator